Venous Thromboembolism – Unmet Need – Detailed, Expanded Analysis (US & EU)
MARKET OUTLOOK
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the NOACs signifies an important milestone for the treatment and secondary prophylaxis of VTE, there are still some areas of unmet need that remain underserved in this patient population. This report examines current treatment performance against treatment goals in the treatment and secondary prophylaxis of DVT and PE from the perspective of emergency room physicians and hematologists. This report also offers insight from these physicians on existing unmet needs for DVT and PE, while our target product profile conjoint simulator demonstrates how various attributes influence these physicians’ prescribing decisions.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for VTE?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for VTE?
- What are the prevailing areas of unmet need and opportunity in VTE?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European emergency room physicians and hematologists for a hypothetical new VTE drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered:United States, France, Germany, and United Kingdom.
Primary research: Survey of 60 U.S. and 31 European emergency room physicians and hematologists fielded in May 2018.
Key companies: Bayer, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, and Janssen Pharmaceuticals.
Key drugs: Pradaxa, Xarelto, Eliquis, and Savaysa/Lixiana.
Table of contents
- Venous Thromboembolism - Unmet Need - Detailed, Expanded Analysis (US & EU)
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Efficacy
- Safety and Tolerability
- Convenience of Administration
- Nonclinical Factors
- Rationale for Drug Selection
- Products for DVT/PE Treatment and Secondary Prophylaxis
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Emergency Room Physicians/Hematologists' Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis
- Importance of Efficacy Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: United States
- Importance of Efficacy Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: United States
- Importance of Nonclinical Factors to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis: United States
- Overall Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis: Europe
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in DVT/PE Treatment and Secondary Prophylaxis
- Surveyed Emergency Room Physicians/Hematologistsu2019 Satisfaction with the Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Emergency Room Physicians/Hematologistsu2019 Satisfaction with the Performance of Key Therapies for DVT/PE Treatment and Secondary Prophylaxis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in DVT/PE Treatment and Secondary Prophylaxis: United States
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in DVT/PE Treatment and Secondary Prophylaxis: United States
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in DVT/PE Treatment and Secondary Prophylaxis: United States
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in DVT/PE Treatment and Secondary Prophylaxis: United States
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in DVT/PE Treatment and Secondary Prophylaxis: Europe
- Key Findings: Unmet Need in DVT/PE Treatment and Secondary Prophylaxis and Related Indications
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need in DVT/PE Treatment and Secondary Prophylaxis and Related Indications: United States
- Surveyed Emergency Room Physicians/Hematologists' Ascribed Level of Unmet Need in DVT/PE Treatment and Secondary Prophylaxis and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the DVT/PE Treatment and Secondary Prophylaxis Market and Emerging Therapy Insights
- Opportunity: A Novel Agent That Reduces the Risk of Bleeding Incidences in VTE Patients
- Opportunity: A Novel Agent That Reduces the Rate of VTE-Related Death
- Areas of Opportunity in the DVT/PE Treatment and Secondary Prophylaxis Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- Deep Vein Thrombosis/Pulmonary Embolism Target Product Profile: Attribute Importance
- Incidence of recurrent DVT
- Incidence of PE
- Incidence of VTE-Related Death
- Incidence of Major Bleeding Events
- Incidence of CRNM Bleeding Events
- Dosing Burden (route and frequency of administration)
- Price per Day
- Conjoint Analysis-Based Simulations of Market Scenarios
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Target Product Profiles Included in Scenario 1
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Target Product Profiles Included in Scenario 2
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 3
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 3
- DVT/PE Treatment and Secondary Prophylaxis Market Simulations: Target Product Profiles Included in Scenario 3
- Appendix
- Key Abbreviations
- Bibliography
- Introduction
Shreya Saxena, M.B.A., is a senior business insights analyst on the Cardiovascular, Metabolic, and Renal Disorders team at DRG, part of Clarivate. Prior to joining DRG, she was a business analyst at the research firm Evalueserve. She obtained her M.B.A. with specializations in marketing and human resources and her bachelor’s degree in pharmacy from GGSIPU University in Delhi, India.